Mostra i principali dati dell'item

dc.contributor.authorSorriento, Daniela
dc.contributor.authorIllario, Maddalena
dc.contributor.authorFinelli, Rosa
dc.contributor.authorIaccarino, Guido
dc.date.accessioned2013-05-29T09:58:33Z
dc.date.available2013-05-29T09:58:33Z
dc.date.issued2012
dc.identifier.citationSorriento D, Illario M, Finelli R, Iaccarino G. To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator. Translational Medicine @ UniSa 2012;4(9):73-85en_US
dc.identifier.issn2239-9747en_US
dc.identifier.urihttp://hdl.handle.net/10556/639
dc.description.abstractNuclear factor B (NFB) is a transcription factor that plays an important role in carcinogenesis as well as in the regulation of inflammatory response. NFB is constitutively expressed in tumours where it induces the expression of genes which promote cell proliferation, apoptotic events, angiogenesis, invasion and metastasis. Furthermore, many cancer cells show aberrant or constitutive NFB activation that mediates resistance to chemo- and radio-therapy. Therefore, the inhibition of NFB activity appears a potential therapeutic strategy for cancer treatment. In this review, we focus on the role of NFB in carcinogenesis and summarize actual inhibitors of NFB that could be potential therapeutic target in cancer therapy.en_US
dc.format.extentP. 73-85en_US
dc.language.isoenen_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectTranscription factorsen_US
dc.subjectIkBen_US
dc.subjectGRK5en_US
dc.subjectCanceren_US
dc.titleTo NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulatoren_US
dc.typeArticleen_US
 Find Full text

Files in questo item

Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item